Trial
NCT02779257
Pasireotide Treatment for Neuroendocrine Tumor
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
Novartis
Condition
Gastro-enteropancreatic Neuroendocrine Tumor
Intervention
Pasireotide
Why stopped
Subject passed away prior to enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-04